H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Oculis to $28 from $29 and keeps a Buy rating on the shares after the company closed a registered direct offering of 5M ordinary shares at $11.75 per share. The firm says multiple clinical catalysts are expected in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
- Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
- Oculis announces listing on Nasdaq Iceland Main Market
- Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
- Oculis names Dr. Snehal Shah as President of Research & Development